Search

Donald W Ruhrmund

from San Francisco, CA
Age ~49
Get Report
Also known as:
Donald William Ruhrmund, Donald Ng Ruhrmund, Donald W Ruhmund
Phone and address:
2178 40Th Ave, San Francisco, CA 94116
(510) 484-6025
Related to:
John Albert Magda, 77Ray D Ruhrmund, 80Ray D RuhrmundJason A Malecha, 42Glenna L RuhrmundAnne C Ruhrmund, 79Elizabeth A Malecha, 44
Connected to:
Michael L Ruhs, 49Tonya M Ruhsenberger, 48Deanna D Ruhter, 41Myrna J Ruhter, 59Rita J Ruhter, 55Robert C Ruhter, 74Craig A Ruhtz, 71Gabriel Ruhumbika, 85Evan Ruhwedel, 36Henry Ruhwiedel, 77

Donald Ruhrmund Phones & Addresses

  • 2178 40Th Ave, San Francisco, CA 94116 (510) 484-6025
  • 2111 47Th Ave, San Francisco, CA 94116
  • 503 Pease Dr, New Carlisle, OH 45344 (937) 845-1582
  • 1726 Stuart St, Berkeley, CA 94703 (510) 540-5886 (510) 649-2962 (510) 665-5877
  • 1505 6Th St, Berkeley, CA 94710 (510) 526-6413
  • Chicago, IL
  • 1726 Stuart St, Berkeley, CA 94703 (510) 540-5886

Work

Position: Production Occupations

Education

Degree: Associate degree or higher

Publications

Us Patents

Compounds And Methods For Treating Inflammatory And Fibrotic Disorders

View page
US Patent:
8304413, Nov 6, 2012
Filed:
Jun 3, 2009
Appl. No.:
12/477715
Inventors:
Karl Kossen - Brisbane CA, US
Scott D. Seiwert - Pacifica CA, US
Vladimir Serebryany - Burlingame CA, US
Donald Ruhrmund - San Francisco CA, US
Leonid Beigelman - San Mateo CA, US
Luca Francesco Mario Raveglia - Milan, IT
Stefania Vallese - Cardano al Campo, IT
Ivana Bianchi - Fagnano Olona, IT
Tao Hu - Shanghai, CN
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A61K 31/50
A61K 31/497
A61K 31/437
A61K 31/44
US Classification:
514247, 5142521, 514300, 514345, 544239, 544408, 546113, 546290
Abstract:
Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

Minrs As Modifiers Of Insulin Receptor Signaling And Methods Of Use

View page
US Patent:
20060088829, Apr 27, 2006
Filed:
Feb 5, 2003
Appl. No.:
10/504120
Inventors:
Arthur Brace - Redwood City CA, US
Agnes Eliares - South San Francisco CA, US
Kimberly Ferguson - Elgranada CA, US
Felipa Mapa - Somerville MA, US
Donald Ruhrmund - San Francisco CA, US
Jianfeng Wu - San Francisco CA, US
International Classification:
C12Q 1/68
G01N 33/53
US Classification:
435006000, 435007100
Abstract:
Human MINR genes are identified as modulators of INR signaling and thus are therapeutic targets for disorders associated with defective INR signaling. Methods for identifying modulators of MINR, comprising screening for agents that modulate the activity of MINR are provided.

Compounds And Methods For Treating Inflammatory And Fibrotic Disorders

View page
US Patent:
20130102597, Apr 25, 2013
Filed:
Oct 15, 2012
Appl. No.:
13/652247
Inventors:
Scott D. Seiwert - Pacifica CA, US
Vladimir Serebryany - Burlingame CA, US
Donald Ruhrmund - San Francisco CA, US
Leonid Beigelman - San Mateo CA, US
Luca Francesco Mario Raveglia - Milano, IT
Stefania Vallese - Cardano al Campo (VA), IT
Ivana Bianchi - Fagnano Olona (VA), IT
Tao Hu - Shanghai, CN
Assignee:
INTERMUNE, INC. - Brisbane CA
International Classification:
C07D 213/63
C07D 213/85
C07D 239/36
C07D 251/10
C07D 239/54
C07D 409/04
C07D 213/69
C07D 405/04
C07D 417/04
C07D 405/14
C07D 413/04
C07D 471/04
C07D 413/14
C07D 417/14
C07D 401/04
US Classification:
5142328, 514345, 514351, 514346, 514256, 514334, 514344, 514274, 514245, 514336, 514342, 514341, 514340, 5142355, 514333, 514300, 51425304
Abstract:
Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

Lpa-Associated Protein And Rna Expression

View page
US Patent:
20170314074, Nov 2, 2017
Filed:
Nov 15, 2016
Appl. No.:
15/351719
Inventors:
- Brisbane CA, US
Sharlene R. Lim - San Mateo CA, US
Scott D. Seiwert - Half Moon Bay CA, US
Donald Ruhrmund - San Francisco CA, US
International Classification:
C12Q 1/68
Abstract:
Provided herein are, inter alia, methods and biomarkers to determine if a patient has or is at risk for developing an LPA-associated disease, to indicate the progressiveness of the disease, and/or to facilitate evaluation of responsiveness to therapy. Compositions and kits including the biomarker proteins and biomarker RNAs provided herein are further provided.

Proteomic Ipf Markers

View page
US Patent:
20140286929, Sep 25, 2014
Filed:
Mar 14, 2014
Appl. No.:
14/213970
Inventors:
- Brisbane CA, US
Xiaoli Qin - San Mateo CA, US
Sharlene R. Lim - San Mateo CA, US
Scott S. Seiwert - Half Moon Bay CA, US
Donald Ruhrmund - San Francisco CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
G01N 33/543
A61K 38/45
A61K 38/46
A61K 38/17
A61K 38/48
US Classification:
424 945, 514 209, 424 9465, 514 212, 424 9467, 424 946, 514 153, 506 9
Abstract:
Provided herein are novel biomarkers for the identification, prediction or monitoring of fibrotic pulmonary diseases (e.g. idiopathic pulmonary fibrosis (IPF)). The biomarkers provided herein may further be used for therapeutic treatment of IPF.

Compounds And Methods For Treating Inflammatory And Fibrotic Disorders

View page
US Patent:
20140235637, Aug 21, 2014
Filed:
Apr 28, 2014
Appl. No.:
14/263822
Inventors:
- Brisbane CA, US
Scott D. Seiwert - Seattle WA, US
Vladimir Serebryany - Burlingame CA, US
Donald Ruhrmund - San Francisco CA, US
Leonid D. Beigelman - San Mateo CA, US
Luca Francesco Mario Raveglia - Milano, IT
Stefania Vallese - Cardano al Campo (VA), IT
Ivana Bianchi - Fagnano Olona (VA), IT
Tao Hu - Shanghai, CN
Assignee:
InterMune, Inc. - Brisbane CA
International Classification:
C07D 213/64
C07D 417/04
C07D 409/04
C07D 405/04
C07D 213/85
US Classification:
5142355, 546290, 514345, 546300, 514351, 546301, 544322, 514256, 546257, 514334, 5462824, 514338, 5462837, 546288, 514344, 5462804, 514336, 5462704, 514342, 544131
Abstract:
Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.
Control profile
Donald W Ruhrmund from San Francisco, CA, age ~49 Get Report